Bevacizumab biosimilar - Beijing Mabworks Biotech

Drug Profile

Bevacizumab biosimilar - Beijing Mabworks Biotech

Alternative Names: MIL-60

Latest Information Update: 12 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Beijing Mabworks Biotech
  • Developer Beijing Mabworks Biotech; Chinese PLA General Hospital
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Non-small cell lung cancer

Most Recent Events

  • 25 Jun 2017 Preclinical trials in Non-small cell lung cancer in China (IV), before June 2017 (Beijing Mabworks Biotech website, June 2017)
  • 25 Jun 2017 Beijing Mabworks Biotech plans a phase III trial for Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease, Recurrent) in China (NCT03196986)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top